Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Motor neuron disease

Urgently needed—biomarkers for amyotrophic lateral sclerosis

The development of disease-modifying therapies for amyotrophic lateral sclerosis (ALS) is a priority for researchers in this field. Two studies have independently identified plasma and cerebrospinal fluid biomarkers for ALS, and these biomarkers could provide a means of testing the efficacy of novel ALS drug treatments in future clinical trials.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Turner, M. R., Kiernan, M. C., Leigh, P. N. & Talbot, K. Biomarkers in amyotrophic lateral sclerosis. Lancet Neurol. 8, 94–109 (2009).

    Article  CAS  Google Scholar 

  2. Mitchell, R. M., Simmons, Z., Beard, J. L., Stephens, H. E. & Connor, J. R. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve 42, 95–103 (2010).

    Article  CAS  Google Scholar 

  3. Ryberg, H. et al. Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve 42, 104–111 (2010).

    Article  CAS  Google Scholar 

  4. Boillee, S. et al. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312, 1389–1392 (2006).

    Article  CAS  Google Scholar 

  5. Brettschneider, J., Petzold, A., Sussmuth, S. D., Ludolph, A. & Tumani, H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 28, 852–856 (2006).

    Article  Google Scholar 

  6. Süssmuth, S. D. et al. CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology 74, 982–987 (2010).

    Article  Google Scholar 

  7. Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130–133 (2006).

    Article  CAS  Google Scholar 

  8. Steinacker, P. et al. TDP-43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch. Neurol. 65, 1481–1487 (2008).

    Article  Google Scholar 

  9. Braak, H., Ludolph, A. C., Thal, D. R & Del Tredici, K. Amyotrophic lateral sclerosis: dash-like accumulation of phosphorylated TDP-43 in somatodendritic and axonal compartments of somatomotor neurons of the lower brainstem and spinal cord. Acta Neuropathol. 120, 67–74 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ludolph, A. Urgently needed—biomarkers for amyotrophic lateral sclerosis. Nat Rev Neurol 7, 13–14 (2011). https://doi.org/10.1038/nrneurol.2010.196

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2010.196

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research